ArticleBriefings in bioinformatics2026
Turning heterogeneity of statistical epistasis networks to an advantage.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Epistasis detection is hindered by multiple challenges, including the proliferation of analytic tools and the diverse methodological choices made in Genome-Wide Association Interaction Studies (GWAIS). These factors often produce inconsistent and only partially overlapping results, with individual methods emphasizing distinct aspects of epistasis. Although comparative evaluations of GWAIS approaches exist, they generally do not identify the factors responsible for methodological discrepancies or assess their implications for biomedical research. Consequently, it remains unclear which features of GWAIS strategies contribute most to these differences and which methods are most appropriate for revealing specific genetic architectures. Here, we present a workflow designed to characterize heterogeneity in GWAIS results and derive practical recommendations systematically. First, we assess non-replicability by comparing single nucleotide polymorphisms-pair rankings and Statistical Epistasis Networks (SENs)-graphs in which nodes represent genetic loci and edges denote epistatic interactions-to identify clusters of protocols with similar outcomes. SENs provide a structured framework for visualizing and comparing variation in epistasis detection, enabling prioritization of interactions recurrently identified across methods. Second, we propose strategies to reduce heterogeneity and enhance robustness, with particular emphasis on interpretability. Notably, we demonstrate that differences among SENs can be informative rather than disadvantageous, as they yield complementary perspectives on disease genetics. Finally, we highlight the benefits of informed SEN aggregation, showing how this approach can strengthen the utility of GWAIS for elucidating biological mechanisms relevant to disease prevention, diagnosis, and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.